Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis: Update Bulletin #1 [February 2018]

Product Code:
596200975
Publication Date:
February 2018
Format:
PDF
Price:
£1,140

This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab) has been approved by the European Commission as a treatment for RRMS and PPMS; Mylan announcing the UK launch of Brabio (glatiramer acetate injection; 40 mg/ml), a generic version of Copaxone; as well as Merck KGaA’s potential FDA resubmission for Mavenclad (cladribine tablets) as a therapy for relapsing forms of MS.

Business Questions:

  • How is Ocrevus expected to be prescribed once launched?
  • Which agents are anticipated to lose market share as a result of Ocrevus’ launch?
  • How do KOLs view Brabio and how successful is it likely to be?
  • How do KOLs view Mavenclad, and how successful has the European launch been?
  • How is Mavenclad currently prescribed?



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved